Oventus Medical reports growth
By HME News Staff
Updated 12:03 PM CDT, Tue August 31, 2021
BRISBANE, Australia – Oventus Medical booked revenues of $1.1 million for the 12 months ended June 30, an increase of 160% over the prior period. “FY21 was Oventus’ best year for device sales on record, despite what remained a highly challenging patient treatment environment for in-person clinical settings, which were heavily tampered by the COVID-19 pandemic,” the company stated. Contributing to Oventus’s growth in the year: lab-in-lab sites that remained operational and the expansion of telehealth within that program; an increase in direct sales to dentists; and the launch of a direct-to-consumer model through its websites (o2vent.com, gopapfree.com and awakexpress.com), supported by telehealth. In fiscal year 2022, the company says it will expand its lower-cost, virtual lab-in-lab program in collaboration with new and existing national partners.
Comments